| human | Q5 |
| P496 | ORCID iD | 0000-0001-5161-8300 |
| P1153 | Scopus author ID | 8138548600 |
| P108 | employer | University of Saskatchewan | Q1514848 |
| P106 | occupation | researcher | Q1650915 |
| Q59355482 | A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3 |
| Q38672711 | A novel combination adjuvant platform for human and animal vaccines. |
| Q40512544 | A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus |
| Q39328333 | Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. |
| Q40552724 | Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity. |
| Q38892934 | Immunostimulatory potential and proteome profiling of Leishmania donovani soluble exogenous antigens |
| Q41531461 | Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients. |
| Q42261596 | Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. |
| Q93013168 | Innate immune protection from pneumonia virus of mice induced by a novel immunomodulator is prolonged by dual treatment and mediated by macrophages |
| Q40076730 | Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus |
| Q40483231 | Intranasal treatment with a novel immunomodulator mediates innate immune protection against lethal pneumonia virus of mice |
| Q33452545 | Leishmania infantum amastigotes enhance HIV-1 production in cocultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-alpha. |
| Q38773273 | Local innate responses and protective immunity after intradermal immunization with bovine viral diarrhea virus E2 protein formulated with a combination adjuvant in cattle. |
| Q40890942 | Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs |
| Q90502975 | Maternal vaccination with a novel chimeric glycoprotein formulated with a polymer-based adjuvant provides protection from human parainfluenza virus type 3 in newborn lambs |
| Q91301730 | Metabolomic and Immunological Profiling of Respiratory Syncytial Virus Infection after Intranasal Immunization with a Subunit Vaccine Candidate |
| Q90147842 | Selection of adjuvants for vaccines targeting specific pathogens |
| Q59360866 | The Major Tegument Protein of Bovine Herpesvirus 1, VP8, Interacts with DNA Damage Response Proteins and Induces Apoptosis |
| Q41630664 | The bovine viral diarrhea virus E2 protein formulated with a novel adjuvant induces strong, balanced immune responses and provides protection from viral challenge in cattle |
| Q41511965 | The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies |
| Q51737656 | The respiratory syncytial virus fusion protein formulated with a polymer-based adjuvant induces multiple signaling pathways in macrophages. |
| Q38068469 | The role of dendritic cells in innate and adaptive immunity to respiratory syncytial virus, and implications for vaccine development. |
| Q45324627 | Vaccination with a human parainfluenza virus type 3 chimeric FHN glycoprotein formulated with a combination adjuvant induces protective immunity |
| Q42235080 | Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. |
Search more.